Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.
- 30 April 1996
- journal article
- case report
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 93 (9) , 3972-3977
- https://doi.org/10.1073/pnas.93.9.3972
Abstract
With efforts underway to develop a preventive human immunodeficiency virus type 1 (HIV-1) vaccine, it remains unclear which immune responses are sufficient to protect against infection and whether prior HIV-1 immunity can alter the subsequent course of HIV-1 infection. We investigated these issues in the context of a volunteer who received six HIV-1LAI envelope immunizations and 10 weeks thereafter acquired HIV-1 infection through a high-risk sexual exposure. In contrast to nonvaccinated acutely infected individuals, anamnestic HIV-1-specific B- and T-cell responses appeared within 3 weeks in this individual, and neutralizing antibody preceded CD8+ cytotoxic responses. Despite an asymptomatic course and an initial low level of detectable infectious virus, a progressive CD4+ cell decline and dysfunction occurred within 2 years. Although vaccination elicited immunity to HIV-1 envelope, which was recalled upon HIV-1 exposure, it was insufficient to prevent infection and subsequent immunodeficiency.Keywords
This publication has 32 references indexed in Scilit:
- Multicenter Evaluation Of Quantification Methods For Plasma Human Immunodeficiency Virus Type 1 RnaThe Journal of Infectious Diseases, 1994
- HIV infection in vaccinated volunteersPublished by American Medical Association (AMA) ,1994
- HIV-Infected Macrophages as Efficient Stimulator Cells for Detection of Cytotoxic T Cell Responses to HIV in Seronegative and Seropositive Vaccine RecipientsAIDS Research and Human Retroviruses, 1994
- Reduced Virus Load in Rhesus Macaques Immunized with Recombinant gp160 and Challenged with Simian Immunodeficiency VirusAIDS Research and Human Retroviruses, 1994
- Immune Responses Elicited by Recombinant Vaccinia-Human Immunodeficiency Virus (HIV) Envelope and HIV Envelope Protein: Analysis of the Durability of Responses and Effect of Repeated BoostingThe Journal of Infectious Diseases, 1994
- Summary of the National Institutes of Health Workshop on Primary Human Immunodeficiency Virus Type 1 Infection1,2AIDS Research and Human Retroviruses, 1993
- Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccineThe Lancet, 1993
- Scientific and Social Issues of Human Immunodeficiency Virus Vaccine DevelopmentScience, 1993
- Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individualsAIDS, 1991
- Plasma Viremia in Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1989